Cargando…

Inflammation, Insulin Resistance, and Type 2 Diabetes: Back to the Future?

Detalles Bibliográficos
Autor principal:	Cefalu, William T.
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2009
Materias:	Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2628602/ https://www.ncbi.nlm.nih.gov/pubmed/19171748 http://dx.doi.org/10.2337/db08-1656

Ejemplares similares

Primary Prevention of Type 2 Diabetes: There Are No Simple Solutions!
por: Cefalu, William T.
Publicado: (2009)

“TODAY” Reflects on the Changing “Faces” of Type 2 Diabetes
por: Cefalu, William T.
Publicado: (2013)

Insulin Resistance and Type 2 Diabetes
por: Taylor, Roy
Publicado: (2012)

Fractalkine: A Cellular Link Between Adipose Tissue Inflammation and Vascular Pathologies
por: Cefalu, William T.
Publicado: (2011)

Back to the Future: Glomerular Hyperfiltration and the Diabetic Kidney
por: Tuttle, Katherine R.
Publicado: (2017)

Back to the Future for Dermatophyte Genomics
por: Rivera, Zeyana S., et al.
Publicado: (2012)

The Intriguing Intersection of Type 2 Diabetes, Obesity-Related Insulin Resistance, and Osteoarthritis
por: Bradley, David
Publicado: (2021)

Health Policy and Diabetes Care: Is It Time to Put Politics Aside?
por: Herman, William H., et al.
Publicado: (2015)

Novel Communications in Diabetes: Another Small but Significant Step for Diabetes Care
por: Cefalu, William T.
Publicado: (2013)

Diabetes Care: Change Is Constant
por: Cefalu, William T.
Publicado: (2012)

Diabetes Care: “State of the Union”
por: Cefalu, William T.
Publicado: (2013)

“New Twist” in Diabetes Care for HbA(1c) Reporting: “It Takes Two to Tango”!
por: Cefalu, William T., et al.
Publicado: (2012)

Diabetes Care to Date: “The Hits Just Keep on Coming!”
por: Cefalu, William T.
Publicado: (2013)

Topics in Type 2 Diabetes and Insulin Resistance
por: Bloomgarden, Zachary T.
Publicado: (2009)

Progress to Date for Diabetes Care: Going mobile and putting information at your fingertips!
por: Cefalu, William T.
Publicado: (2012)

Back to the future but better
por: Brewster, Luke
Publicado: (2020)

“Prediction Is Very Hard, Especially About the Future”: New Biomarkers for Type 2 Diabetes?
por: Lowe, William L., et al.
Publicado: (2013)

Novel Link Between Inflammation, Endothelial Dysfunction, and Muscle Insulin Resistance
por: Mauvais-Jarvis, Franck
Publicado: (2013)

The Value of Insulin Degludec in Frail Older Adults with Type 2 Diabetes
por: Strain, W. David, et al.
Publicado: (2021)

Translating “Nondiabetic” A1C Levels to Clinical Practice: The Art of Medicine
por: Cefalu, William T.
Publicado: (2010)

Cardiovascular safety of long‐acting insulin analogs in type 2 diabetes patients: Is there a better basal insulin?
por: Chang, Chia‐Hsuin, et al.
Publicado: (2017)

Endoplasmic Reticulum Stress: Another Link Between Obesity and Insulin Resistance/Inflammation?
por: Boden, Guenther
Publicado: (2009)

CCR5: A novel player in the adipose tissue inflammation and insulin resistance?
por: Ota, Tsuguhito
Publicado: (2013)

A role for 5-lipoxygenase products in obesity-associated inflammation and insulin resistance
por: Neels, Jaap G
Publicado: (2013)

Therapeutic Monitoring of Direct Oral Anticoagulants—Back to the Future?
por: Hu, Kai, et al.
Publicado: (2020)

Loss of Pulsatile Insulin Secretion: A Factor in the Pathogenesis of Type 2 Diabetes?
por: Wahren, John, et al.
Publicado: (2012)

Selecting Insulin Regimens for the Management of Non-ICU Patients With Type 2 Diabetes
por: Migdal, Alexandra L, et al.
Publicado: (2021)

Exercise in type 2 diabetes: to resist or to endure?
por: Roden, M.
Publicado: (2012)

One Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus
por: Evans, Marc, et al.
Publicado: (2021)

Reevaluation of CMS’ Competitive Bidding Program
por: Schatz, Desmond, et al.
Publicado: (2016)

From Programs to Policy and Back Again: The Push and Pull of Realizing Type 2 Diabetes Prevention on a National Scale
por: Ackermann, Ronald T.
Publicado: (2017)

Delineating the transcriptional atlas for impaired insulin secretion: A window into type 2 diabetes pathophysiology
por: Li, Jian, et al.
Publicado: (2023)

The Type 1 Diabetes Signature: Hardwired to Trigger Inflammation?
por: Coppieters, Ken T., et al.
Publicado: (2014)

Looking back to look forward: Surviving COVID-19 and the future of the NHS
por: Vacek, Adam, et al.
Publicado: (2023)

Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?
por: Home, Philip, et al.
Publicado: (2014)

Steps Toward the Meaningful Translation of Prevention Strategies for Type 2 Diabetes
por: Cefalu, William T.
Publicado: (2012)

Is Endogenous GLP-1 the Only Important Enhancer of Glucose-Induced Insulin Secretion in Type 2 Diabetes?
por: Deacon, Carolyn F.
Publicado: (2012)

GLUT12: a second insulin‐responsive glucose transporters as an emerging target for type 2 diabetes
por: Matsuzaka, Takashi, et al.
Publicado: (2011)

Metformin induces insulin secretion by preserving pancreatic aquaporin 7 expression in type 2 diabetes mellitus
por: Kimura, Tomohiko, et al.
Publicado: (2021)

Commentary to “Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec” by Kawaguchi et al. Diabetes Therapy 2019
por: Pieber, Thomas R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lrpplq5bgs2q8lpb86mgq7e3eh